Increased Neural Responses to Reward in Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Their Unaffected Siblings - 19/04/15
Abstract |
Objective |
Attention-deficit/hyperactivity disorder (ADHD) is a heritable neuropsychiatric disorder associated with abnormal reward processing. Limited and inconsistent data exist about the neural mechanisms underlying this abnormality. Furthermore, it is not known whether reward processing is abnormal in unaffected siblings of participants with ADHD.
Method |
We used event-related functional magnetic resonance imaging (fMRI) to investigate brain responses during reward anticipation and receipt with an adapted monetary incentive delay task in a large sample of adolescents and young adults with ADHD (n = 150), their unaffected siblings (n = 92), and control participants (n = 108), all of the same age.
Results |
Participants with ADHD showed, relative to control participants, increased responses in the anterior cingulate, anterior frontal cortex, and cerebellum during reward anticipation, and in the orbitofrontal, occipital cortex and ventral striatum. Responses of unaffected siblings were increased in these regions as well, except for the cerebellum during anticipation and ventral striatum during receipt.
Conclusion |
ADHD in adolescents and young adults is associated with enhanced neural responses in frontostriatal circuitry to anticipation and receipt of reward. The findings support models emphasizing aberrant reward processing in ADHD, and suggest that processing of reward is subject to familial influences. Future studies using standard monetary incentive delay task parameters are needed to replicate our findings.
Le texte complet de cet article est disponible en PDF.Key Words : ADHD, reward processing, cognitive control, familiality, nucleus accumbens
Plan
This work was supported by National Institutes of Health (NIH) grant R01MH62873 (SF), NWO Large Investment Grant 1750102007010 (JB), and grants from Radboud University Medical Center, University Medical Center Groningen and Accare, and VU University Amsterdam. |
|
Drs. Mennes, Cools, Zwiers, Buitelaar, and Mr. von Rhein served as the statistical experts for this research. |
|
Disclosure: Dr. Cools has served as a consultant to Abbott Laboratories and Pfizer. Dr. Oosterlaan has received an investigator initiated grant from Shire. Dr. Hoekstra has received advisory panel payments from Shire as well as an unrestricted research grant from Shire. Dr. Faraone has received consulting income, travel expenses, and/or research support from, and/or has served on the advisory board of Pfizer, Ironshore, Shire, Akili Interactive Labs, Alcobra, CogCubed, Impax, NeuroLifeSciences, VAYA Pharma, and Neurovance, and research support from NIH. His institution (SUNY) is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he has received consulting fees or served on advisory boards or participated in continuing medical education programs sponsored by Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly and Co. He has received royalties from books published by Guilford Press (Straight Talk about Your Child’s Mental Health) and Oxford University Press (Schizophrenia: The Facts). Dr. Buitelaar has served as a consultant to/member of advisory board of/speaker for Janssen Cilag BV, Eli Lilly and Co., Bristol-Myers Squibb, Shering Plough, UCB, Shire, Novartis, and Servier. Drs. Zwiers, van der Schaaf, Franke, Luman, Heslenfeld, Hartman, van Dongen, and Mennes, Mr. von Rhein, Mr. van Rooij, and Ms. Lojowska report no biomedical financial interests or potential conflicts of interest. |
Vol 54 - N° 5
P. 394-402 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?